Optical method for detecting Alzheimer's disease by systemic administration of curcumin

Patent metadata

Field	Value
Publication number	US-9839699-B2
Application number	US-200913119596-A
Country	US
Kind code	B2
Filing date	Sep 18, 2009
Priority date	Sep 18, 2008
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

First claim

What is claimed is:

1. A method of diagnosing Alzheimer's disease in vivo in a mammal, comprising systemically administering curcumin to the mammal for staining retinal Aβ peptides; imaging the mammal's retina with an optical imaging system suitable for visualizing Aβ peptides present in the ganglion cell layer (“GCL”) of the mammal's retina; examining the images for stained Aβ peptides present in the GCL of the mammal's retina; and diagnosing the mammal as having Alzheimer's disease if stained Aβ peptides are present in the GCL of the mammal's retina.

2. The method of claim 1 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a charge-coupled device (“CCD”) gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

3. The method of claim 1 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

4. The method of claim 1 , wherein the mammal is a human.

5. A method of identifying Aβ peptides in a mammal's retina in vivo, comprising systemically administering curcumin to the mammal for staining the retinal Aβ peptides; imaging the mammal's retina with an optical imaging system suitable for visualizing Aβ peptides present in the GCL of the mammal's retina; and examining the images for stained Aβ peptides present in the GCL of the mammal's retina.

6. The method of claim 5 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

7. The method of claim 5 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

8. The method of claim 5 , wherein the mammal is a human.

9. A method of diagnosing Alzheimer's disease in vivo in a mammal, comprising systemically administering curcumin to the mammal for staining retinal Aβ plaques; imaging the mammal's retina with an optical imaging system suitable for visualizing Aβ plaques present in the GCL of the mammal's retina; examining the images for stained Aβ plaques present in the GCL of the mammal's retina; and diagnosing the mammal as having Alzheimer's disease if stained Aβ plaques are present in the GCL of the mammal's retina.

10. The method of claim 9 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

11. The method of claim 9 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

12. The method of claim 9 , wherein the mammal is a human.

13. A method of identifying Aβ plaques in a mammal's retina in vivo, comprising systemically administering curcumin to the mammal for staining the retinal Aβ plaques; imaging the mammal's retina with an optical imaging system suitable for visualizing Aβ plaques present in the GCL of the mammal's retina; and examining the images for stained Aβ plaques present in the GCL of the mammal's retina.

14. The method of claim 13 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

15. The method of claim 13 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

16. The method of claim 13 , wherein the mammal is a human.

Assignees

• Koronyo Yosef
• Koronyo Maya
• Black Keith L
• Schwartz Michal
• Farkas Daniel L
• Yeda Res & Dev
• Cedars Sinai Medical Center

Inventors

• Koronyo Yosef
• Koronyo Maya
• Black Keith L
• Schwartz Michal
• Farkas Daniel L

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/12

  for cataracts · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title